s:**
- Single-cell RNA-seq to measure editing efficiency across different CNS cell types
- Genome-wide off-target analysis in edited brain tissue
- Lo
Background and Rationale
CRISPR-based Gene Editing Efficiency and Safety Assessment in Central Nervous System Models for ALS Research
This falsification experiment aims to critically evaluate the efficacy and safety profile of CRISPR-Cas9 mediated gene editing across distinct central nervous system (CNS) cell types relevant to amyotrophic lateral sclerosis (ALS) pathogenesis. The study addresses a fundamental gap in translational neuroscience by combining single-cell transcriptomic analysis with comprehensive off-target assessment and behavioral validation in animal models. The underlying rationale stems from the critical need to understand cell-type-specific editing efficiency and potential unintended genomic modifications before advancing CRISPR-based therapeutics for neurological diseases. While CRISPR technology has demonstrated remarkable potential for treating genetic disorders, its application in the CNS presents unique challenges including variable transduction efficiency across neuronal and glial populations, potential off-target effects that may exacerbate neuroinflammation, and the difficulty in predicting functional consequences of editing in complex neural circuits. This experiment is designed to falsify the assumption that CRISPR editing achieves uniform efficiency across CNS cell types without generating clinically significant off-target effects.
The experimental approach employs both in vitro and in vivo components to establish a comprehensive safety and efficacy profile. In vitro studies utilize differentiated motor neuron progenitor cell lines derived from human induced pluripotent stem cells (iPSCs), astrocytes, and microglia-like cells generated from the same genetic background. These cell types represent the primary pathological players in ALS, with motor neurons representing the primary target for therapeutic intervention, while astrocytes and microglia contribute significantly to disease progression through neuroinflammatory mechanisms. Cells are cultured under standard conditions and transduced with adeno-associated viral (AAV) vectors carrying a SpCas9 variant optimized for CNS delivery, paired with a guide RNA targeting a validated ALS-associated locus such as SOD1, FUS, or C9ORF72, depending on the specific disease model. To establish baseline comparisons, parallel cultures receive either non-targeting control guide RNAs or mock transduction with empty vectors. Transduction efficiency is standardized across cell types by adjusting viral titer to achieve approximately 40-60% of cells expressing the transgene, as confirmed by fluorescent protein markers linked to the Cas9 construct. This moderate efficiency range is deliberately chosen to reflect realistic therapeutic scenarios where complete cellular transduction is unlikely.
Single-cell RNA-sequencing (scRNA-seq) constitutes the primary analytical methodology for assessing editing outcomes. Edited and control cells are harvested at three distinct timepoints: 72 hours post-transduction (early editing phase), 14 days post-transduction (late editing phase), and 28 days post-transduction (chronic exposure phase). At each timepoint, cells are processed using 10x Genomics platform technology to generate transcriptomic profiles of individual cells, enabling identification of successfully edited versus unedited cells through detection of anticipated indels at the target locus via deep sequencing. This approach provides both editing efficiency estimates and reveals cell-type-specific responses to the editing process. The scRNA-seq data are analyzed for off-target transcriptomic effects, including unanticipated changes in inflammatory pathways, apoptotic markers, cell cycle progression, or stress response genes that might indicate cellular distress from the editing process itself.
Genome-wide off-target analysis is performed using whole-genome sequencing (WGS) at 100x coverage on bulk populations of edited and control cells at the 14-day and 28-day timepoints. The sequencing data are analyzed using established bioinformatic pipelines designed to identify off-target CRISPR-Cas9 editing sites based on sequence homology and predicted on-target cutting probability. Conservative thresholds are applied to identify potential off-target sites with greater than 80 percent sequence homology to the intended guide RNA. Any identified off-target modifications are validated using targeted deep sequencing and, if present, characterized for potential functional consequences through assessment of whether they occur within coding sequences or regulatory regions.
The in vivo component employs a well-established ALS disease model, specifically transgenic SOD1-G93A mice expressing human mutant superoxide dismutase-1. These mice develop progressive motor neuron degeneration with characteristic behavioral deficits beginning around 8-10 weeks of age and reaching end-stage disease by 16-20 weeks. Two cohorts of animals are established: an experimental group receiving intracerebroventricular injection of AAV vectors carrying Cas9 and guide RNAs targeting disease-relevant loci, and a control group receiving intracerebroventricular injection of empty vector or vehicle alone. Both cohorts also include age-matched wild-type littermates to establish baseline cognitive and motor function. The injections are performed at 6 weeks of age, prior to disease symptom onset, allowing assessment of both disease prevention and potential adverse effects of editing on early behavioral development.
Longitudinal cognitive testing begins at 8 weeks of age and continues biweekly through 18 weeks of age, encompassing both pre-symptomatic and symptomatic disease phases. The testing battery includes Morris water maze assessment for spatial learning and memory, novel object recognition testing for cognitive function, and rotarod testing for motor coordination and performance. Motor phenotyping additionally incorporates grip strength measurements and detailed kinematic analysis of locomotor parameters. Behavioral testing is conducted by experimenters blinded to treatment assignment to minimize bias. Tissue from edited animals is collected at 12 weeks and 18 weeks of age for scRNA-seq and WGS analysis using the same protocols employed in vitro, enabling direct comparison of editing efficiency and off-target effects between cell culture and intact CNS environments.
Expected outcomes include demonstration of cell-type-specific variation in editing efficiency, with motor neurons potentially showing lower transduction efficiency than glial cells depending on viral tropism. The scRNA-seq analysis is anticipated to reveal modest transcriptional stress responses in edited cells, including upregulation of heat shock proteins and interferon-responsive genes, which would be consistent with known cellular responses to CRISPR components. The genome-wide off-target analysis may identify multiple potential off-target sites with modest cutting probability, though the functional significance of these modifications remains uncertain. The in vivo studies are expected to show modest improvements in motor performance and extended survival in edited SOD1-G93A mice if the therapeutic intervention successfully modulates disease pathogenesis, while cognitive and behavioral measures in wild-type animals should remain unaffected by editing procedures.
Success criteria for falsifying the initial assumption include demonstration of significant heterogeneity in editing efficiency across CNS cell types (greater than 30 percent variation in editing rates), identification of off-target modifications in coding regions with potential functional consequences, or evidence of unexpected cognitive or behavioral deficits in edited animals despite successful target locus modification. Challenges anticipated include achieving sufficient AAV transduction in the intact brain, managing viral toxicity responses that may confound interpretation of editing effects, and controlling for stochastic variation in both single-cell transcriptomic sampling and behavioral phenotyping. The experiment is powered to detect clinically meaningful changes in these parameters while remaining feasible within standard laboratory timelines and resource constraints.
This experiment directly tests predictions arising from the following hypotheses:
- Cryptic Exon Silencing Restoration
- Cross-Seeding Prevention Strategy
- Axonal RNA Transport Reconstitution
- R-Loop Resolution Enhancement Therapy
- Glycine-Rich Domain Competitive Inhibition
Experimental Protocol
Phase 1: Cell Line Preparation and Editing (Weeks 1-2)• Culture human iPSC-derived motor neurons (n=6 lines) and astrocytes (n=6 lines) representing ALS disease models
• Prepare CRISPR-Cas9 editing constructs targeting ALS-associated genes (SOD1, C9orf72, TARDBP)
• Perform electroporation-based gene editing with guide RNAs at 48-hour intervals
• Maintain edited and control cell lines in parallel cultures with standard media conditions
Phase 2: Single-cell RNA-seq Analysis (Weeks 3-4)
• Harvest cells at 7, 14, and 21 days post-editing (n=10,000 cells per timepoint per line)
• Process samples using 10x Genomics Chromium platform for scRNA-seq library preparation
• Sequence libraries to achieve >50,000 reads per cell with >80% saturation
• Perform bioinformatics analysis using Seurat pipeline for cell type identification and editing efficiency quantification
• Calculate on-target editing rates using CRISPResso2 analysis of aligned reads
Phase 3: Genome-wide Off-target Detection (Weeks 4-5)
• Extract genomic DNA from edited cell populations at day 14 post-editing
• Perform CIRCLE-seq analysis to identify potential off-target sites genome-wide
• Validate top 20 predicted off-target sites using targeted deep sequencing (>10,000x coverage)
• Conduct GUIDE-seq analysis as orthogonal validation method for off-target detection
• Analyze chromosomal integrity using karyotype analysis and copy number variation detection
Phase 4: Functional Validation and Phenotypic Analysis (Weeks 5-6)
• Assess cell viability using MTT assays and flow cytometry analysis at multiple timepoints
• Measure ALS-relevant protein aggregation using immunofluorescence microscopy
• Quantify neurite outgrowth and synaptic marker expression in motor neuron cultures
• Perform electrophysiological recordings to assess neuronal activity and excitability changes
• Analyze astrocyte activation markers and inflammatory cytokine production
Expected Outcomes
On-target editing efficiency of 60-85% in motor neurons and 45-70% in astrocytes, with motor neurons showing higher editing rates due to enhanced Cas9 delivery
Detection of 5-15 high-confidence off-target sites per guide RNA, with <2% off-target editing frequency at validated sites
Cell type-specific transcriptional responses with >500 differentially expressed genes (FDR<0.05, |log2FC|>0.5) in edited vs control populations
Maintenance of >90% cell viability in edited populations compared to controls throughout the 21-day observation period
Reduced protein aggregation (30-50% decrease) in successfully edited ALS model cell lines compared to unedited disease controls
No significant chromosomal abnormalities or large structural variants in >95% of edited cell clonesSuccess Criteria
• Achieve >70% on-target editing efficiency in at least 4 out of 6 motor neuron cell lines with statistical significance (p<0.01)
• Demonstrate <5% off-target editing frequency at all validated sites with confirmation by two independent methods
• Obtain high-quality scRNA-seq data from >8,000 cells per condition with >2,000 genes detected per cell
• Maintain cell viability >85% compared to controls with no significant difference in proliferation rates (p>0.05)
• Complete genome-wide off-target analysis with >95% genome coverage and validation of top 20 predicted sites
• Successfully differentiate edited and control cell populations using unsupervised clustering analysis (ARI>0.7)